Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ABIVAX Société Anonyme stock logo
ABVX
ABIVAX Société Anonyme
$6.00
-0.2%
$6.25
$4.77
$14.71
$380.62M0.29142,159 shs130,094 shs
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
$3.62
+1.4%
$4.65
$3.35
$22.00
$93.66MN/A82,583 shs58,846 shs
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$2.77
-2.8%
$4.04
$2.28
$6.71
$351.39M1.851.18 million shs803,613 shs
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
$7.88
$2.67
$1.31
$7.95
$367.78M1.9654,958 shs1.21 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ABIVAX Société Anonyme stock logo
ABVX
ABIVAX Société Anonyme
+5.81%-0.66%-15.59%-21.74%-54.19%
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
+5.00%-8.70%-19.05%-49.29%-76.74%
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
-0.70%-4.04%-41.60%-54.19%+10.89%
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
-0.13%0.00%+310.42%+225.62%+165.32%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ABIVAX Société Anonyme stock logo
ABVX
ABIVAX Société Anonyme
2.7201 of 5 stars
3.54.00.00.02.90.80.6
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
2.3343 of 5 stars
3.62.00.00.03.20.80.6
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
4.0879 of 5 stars
3.31.00.04.33.33.30.6
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
3.155 of 5 stars
4.03.00.00.02.32.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ABIVAX Société Anonyme stock logo
ABVX
ABIVAX Société Anonyme
3.00
Buy$31.00416.67% Upside
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
3.20
Buy$22.50521.55% Upside
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
2.50
Moderate Buy$5.5098.56% Upside
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
2.00
Hold$10.8037.06% Upside

Current Analyst Ratings Breakdown

Latest CTNM, VIGL, ORGO, and ABVX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$11.00 ➝ $8.00
5/27/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$14.00 ➝ $8.00
5/23/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Neutral$8.00
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeMarket Perform
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Perform
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$13.00 ➝ $8.00
5/19/2025
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$25.00 ➝ $20.00
(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ABIVAX Société Anonyme stock logo
ABVX
ABIVAX Société Anonyme
N/AN/AN/AN/A$3.37 per shareN/A
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
$50M1.87$0.57 per share6.35($3.72) per share-0.97
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$458.76M0.77$0.18 per share15.72$2.11 per share1.31
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
N/AN/AN/AN/A$3.24 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ABIVAX Société Anonyme stock logo
ABVX
ABIVAX Société Anonyme
-$159.90MN/A0.00N/AN/AN/AN/AN/A6/2/2025 (Estimated)
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
$22.72M-$1.97N/AN/AN/AN/A-49.92%-20.52%8/12/2025 (Estimated)
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$4.95M-$0.17N/AN/AN/A-1.62%-2.69%-1.63%8/14/2025 (Estimated)
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
-$82.64M-$2.05N/AN/AN/AN/A-83.89%-65.34%8/12/2025 (Estimated)

Latest CTNM, VIGL, ORGO, and ABVX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/2/2025Q1 2025
ABIVAX Société Anonyme stock logo
ABVX
ABIVAX Société Anonyme
-$1.5884N/AN/AN/A$3.11 millionN/A
5/14/2025Q1 2025
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-$0.56-$0.62-$0.06-$0.62$7.50 millionN/A
5/8/2025Q1 2025
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$0.04-$0.13-$0.17-$0.17$90.77 million$86.69 million
5/7/2025Q1 2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
-$0.53-$0.49+$0.04-$0.49N/AN/A
3/13/2025Q4 2024
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
-$0.49-$0.57-$0.08-$0.57N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ABIVAX Société Anonyme stock logo
ABVX
ABIVAX Société Anonyme
N/AN/AN/AN/AN/A
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/AN/AN/AN/AN/A
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ABIVAX Société Anonyme stock logo
ABVX
ABIVAX Société Anonyme
0.48
3.04
N/A
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/A
37.06
37.06
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
0.21
3.09
2.74
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
N/A
3.72
3.72

Institutional Ownership

CompanyInstitutional Ownership
ABIVAX Société Anonyme stock logo
ABVX
ABIVAX Société Anonyme
47.91%
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/A
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
49.57%
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
83.64%

Insider Ownership

CompanyInsider Ownership
ABIVAX Société Anonyme stock logo
ABVX
ABIVAX Société Anonyme
N/A
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
11.30%
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
33.00%
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
18.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
ABIVAX Société Anonyme stock logo
ABVX
ABIVAX Société Anonyme
6163.44 millionN/ANot Optionable
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
3125.87 millionN/AN/A
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
950126.85 million79.33 millionOptionable
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
4046.67 million27.38 millionNot Optionable

Recent News About These Companies

Stifel Downgrades Vigil Neuroscience (VIGL)
Q2 EPS Estimate for Vigil Neuroscience Boosted by Analyst
Mizuho Downgrades Vigil Neuroscience (NASDAQ:VIGL) to Hold

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABIVAX Société Anonyme stock logo

ABIVAX Société Anonyme NASDAQ:ABVX

$6.00 -0.01 (-0.17%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Contineum Therapeutics stock logo

Contineum Therapeutics NASDAQ:CTNM

$3.62 +0.05 (+1.40%)
Closing price 04:00 PM Eastern
Extended Trading
$3.66 +0.04 (+1.24%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$2.77 -0.08 (-2.81%)
Closing price 04:00 PM Eastern
Extended Trading
$2.85 +0.08 (+2.89%)
As of 06:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Vigil Neuroscience stock logo

Vigil Neuroscience NASDAQ:VIGL

$7.88 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$7.87 -0.01 (-0.13%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.